Thank you for donating!

You can donate using the following services.


  1. 24.05.19

    CTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol® Cyclo™ for Niemann-Pick Disease Type C

    ALACHUA, FL – (Accesswire) – May 23, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced its first home-based infusion of its proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, in a formal clinical trial. The trial is “An Open-Label Extension Study of the Long-Term Safety and Efficacy of Intravenous Trappsol® Cyclo™ (HPBCD) in Patients with Niemann-Pick Disease Type C (NPC-1)” ( NCT03893071) in the United States.

    Read more
  2. 13.05.19

    Professional Delegate Interactive Workshop and Conference Registration Form - 2019

    NPUK INTERACTIVE WORKSHOP - REGISTER NOW! For all health professionals, clinicians and pharma reps who want to join us for the Interactive Workshop this form is for you, please register by the 6th September.

    Read more
  3. 13.05.19

    26th NPUK Annual Family Conference 2019 (Registration Form)

    NPUK ANNUAL FAMILY CONFERENCE - REGISTER NOW! Don't miss out on your chance to join the NPUK Annual Family Conference, the biggest and best event in our calendar! Which this year will be held on the 20th-22nd September at Wyboston Lakes, Bedfordshire.

    Read more
  4. 09.05.19

    Mallinckrodt - VTS-270-303 (9/5/19)

    An update from Mallinckrodt Pharmaceuticals regarding their study VTS-270-303...

    Read more
  5. 07.05.19

    NPUK News: Spring 2019

    We are happy to announce that the latest edition of NPUK News (Spring 2019) is here, full to the brim with everything our community needs - there's fundraising stories, events news, updates from staff and community members...and so much more!

    Read more